Cargando…
P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY.
Autores principales: | Moshe, Yakir, Levi, Shai, Neeman, Miri, Gat, Roi, Levi, Mor, Eilati, Nili, Shragai, Tamir, Basood, May, Segman, Yafit, Baron, Yaeli, Luttwak, Efrat, Neuman, Tsipora, Vitkon, Roy, Mittelman, Moshe, Avivi, Irit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428728/ http://dx.doi.org/10.1097/01.HS9.0000969144.75498.e6 |
Ejemplares similares
-
P571: OUTPATIENT INITIATION OF VENETOCLAX-AZACITIDINE FOR SELECTED ACUTE MYELOID LEUKEMIA PATIENTS IS FEASIBLE AND SAFE: A REAL WORLD SINGLE CENTER ANALYSIS
por: Gat, Roi, et al.
Publicado: (2023) -
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
por: Bronstein, Yotam, et al.
Publicado: (2022) -
Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma
por: Atar, Or, et al.
Publicado: (2023) -
Daratumumab in combination with proteasome inhibitors, rapidly
decreases polyclonal immunoglobulins and increases infection risk among relapsed
multiple myeloma patients: a single center retrospective study
por: Vitkon, Roy, et al.
Publicado: (2021) -
Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem
por: Basood, May, et al.
Publicado: (2018)